Clinical Specialist - BMT
- West Virginia University WVU Cancer Institute
- Alexander B. Osborn Hematopoietic Malignancy and Transplantation Program Clinical Service
- PharmD, West Virginia University, 2001
Ten most recent:
Superior serum concentrations with posaconazole delayed-release tablets compared to suspension formulation in hematological malignancies.
Cumpston AD, Caddell R, Shillingburg A, Lu X, Wen S, Hamadani M, Craig M, Kanate AS.
Antimicrob Agents Chemother. 2015;59(8):4424-4428.
Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.
Veltri L, Cumpston AD, Shillingburg AS, Wen S, Luo J, Leadmon S, Watkins K, Craig M, Hamadani M, Kanate AS.
Diacetyl increases sensory innervation and substance p production in rat trachea.
Goravanahally MP, Hubbs AF, Fedan JS, Kashon ML, Battelli LA, Mercer RR, Goldsmith WT, Jackson MC, Cumpston AD, Frazer DG, Dey RD.
Toxicol Pathol. 2014;42(3):582-590.
Predictors and impact of thirty-day readmission on patient outcomes and health care costs after reduced-toxicity conditioning allogeneic hematopoietic cell transplantation.
Rauenzahn S, Truong Q, Cumpston AD, Goff L, Leadmon S, Evans K, Zhang J, Wen S, Craig M, Hamadani M, Kanate AS.
Biol Blood Marrow Transplant. 2014;20(3):415-420.
Impact of the duration of antiviral prophylaxis on rates of varicella-zoster virus reactivation disease in autologous hematopoietic cell transplantation recipients.
Truong Q, Veltri L, Kanate AS, Hu Y, Craig M, Hamadani M, Cumpston AD.
Ann Hematol. 2014;93(4):677-682.
Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies.
Awan FT, Kochuparambil ST, Falconer DE, Cumpston AD, Leadmon S, Watkins K, DeRemer D, Jillella A, Craig M, Hamadani M.
Bone Marrow Transplant. 2013;48(10):1279-1284.
Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
Chaudhary LN, Awan FT, Cumpston AD, Leadmon S, Watkins K, Tse WW, Craig M, Hamadani M.
J Clin Apher. 2013;28(5):359-367.
Extended follow-up of an antibiotic cycling program for the management of febrile neutropenia in a hematologic malignancy and hematopoietic cell transplantation unit.
Cumpston AD, Craig M, Hamadani M, Abraham J, Hobbs GR, Sarwari AR.
Transpl Infect Dis. 2013;15(2):142-149.
Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease.
Hamadani M, Gibson LF, Remick SC, Wen S, Petros WP, Tse WW, Brundage KM, Vos JA, Cumpston AD, Bunner P, Craig M.
J Clin Oncol. 2013;31(35):4416-4423.
Salvage bone marrow harvest in patients failing Plerixafor-based stem cell mobilization attempt: feasibility and autologous transplantation outcomes.
Kanate AS, Watkins K, Cumpston AD, Craig M, Hamadani M.
Biol Blood Marrow Transplant. 2013;19(7):1133-1135.
Alexander B. Osborn Hematopoietic Malignancy and Transplantation Program